Muscle wasting in chronic kidney disease: The role of the ubiquitin proteasome system and its clinical impact

Pediatric Nephrology

Volumn 23, Issue 4, 2008, Pages 527-535

  Rajan, Vik R ^a   Mitch, William E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

14kD actin fragment; Caspase 3; Chronic kidney disease (CKD); Muscle atrophy; Muscle wasting; Protein degradation; Ubiquitin proteasome system (UPS); Uremia

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATE; AMINO ACID; BIOLOGICAL MARKER; CASPASE 3; MUSCLE PROTEIN; MYOSIN; PROTEASOME; TROPOMYOSIN; TROPONIN; UBIQUITIN;

CHRONIC KIDNEY DISEASE; DIETARY INTAKE; ENZYME ACTIVATION; ENZYME ACTIVITY; HEMODIALYSIS PATIENT; HUMAN; IMMUNE RESPONSE; METABOLIC ACIDOSIS; MUSCLE ATROPHY; MUSCLE FIBRIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UREMIA;

HUMANS; MUSCLE PROTEINS; MUSCULAR ATROPHY; PROTEASOME ENDOPEPTIDASE COMPLEX; RENAL INSUFFICIENCY, CHRONIC; UBIQUITIN;

EID: 40549124049     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0594-z     Document Type: Review

References (91)

1. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J (1998) Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53:773-782
2. Kopple JD (2001) National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 37:S66-S70
3. Mitch WE (2002) Malnutrition: A frequent misdiagnosis for hemodialysis patients. J Clin Invest 110:437-439
4. Kaysen GA, Dubin JA, Muller H-G, Rosales L, Levin NW, Mitch WE (2004) Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 65:1408-1415
5. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE (1996) The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent, ubiquitin-proteasome pathway. J Clin Invest 97:1447-1453
6. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, Phillips LS, Mitch WE (1996) Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome pathway by a mechanism including gene transcription. J Clin Invest 98:1703-1708
7. Song Y-H, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P (2005) Muscle-specific expression of insulin-like growth factor-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115:451-458
8. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T (1999) Strong association between malnutrition, inflammation and atherosclerosis in chronic kidney failure. Kidney Int 55:1899-1911
9. Lim VS, Kopple JD (2000) Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis. Kidney Int 58:1-10
10. Mitch WE, Goldberg AL (1996) Mechanisms of muscle wasting: The role of the ubiquitin-proteasome system. N Engl J Med 335:1897-1905
11. Pickering WP, Price SR, Bircher G, Marinovic AC, Mitch WE, Walls J (2002) Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 61:1286-1292
12. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82:373-428
13. Pickart CM (2004) Back to the future with ubiquitin. Cell 116:181-190
14. Baumeister W, Walz J, Zuhl F, Seemuller E (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367-380
15. Lecker SH, Goldberg AL, Mitch WE (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17:1807-1819
16. Muratani M, Tansey WP (2003) How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4:192-201
17. Lipford JR, Smith GT, Chi Y, Deshaies RJ (2005) A putative stimulatory role for activator turnover in gene expression. Nature 438:113-116
18. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663
19. Kisselev AF, Akopian TN, Woo KM, Goldberg AL (1999) The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 274:3363-3371
20. Adams J (2004) The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360
21. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell 78:773-785
22. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: From research tools to drug candidates. Chem Biol 8:739-758
23. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR (1995) Multiple proteolytic systems, including the proteasome contribute CFTR processing. Cell 83:129-135
24. Meusser B, Hirsch C, Jarosch E, Sommer T (2005) ERAD: The long road to destruction. Nat Cell Biol 7:766-772
25. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class 1 molecules. Cell 78:761-771
26. Hicke L, Dunn R (2003) Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19:141-172
27. Sigismund S, Polo S, Di Fiore PP (2004) Signaling through monoubiquitination. Curr Top Microbiol Immunol 286:149-185
28. Lecker SH, Jagoe RT, Gomes M, Baracos V, Bailey JL, Price SR, Mitch WE, Goldberg AL (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18:39-51
29. Mansoor O, Beaufrere Y, Boirie Y, Ralliere C, Taillandier D, Aurousseau E, Schoeffler P, Arnal M, Attaix D (1996) Increased mRNA levels for components of the lysosomal, Ca++-activated and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients. Proc Natl Acad Sci USA 93:2714-2718
30. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasselgren P-O (1997) Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 99:163-168
31. Williams AB, Sun X, Fischer JE, Hasselgren P-O (1999) The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 126:744-749
32. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR (1999) Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 276:C1132-C1138
33. Tawa NE, Odessey R, Goldberg AL (1997) Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 100:197-203
34. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clark BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuel DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704-1708
35. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE (2004) Regulation of muscle protein degradation: Coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 15:1537-1545
36. Sandri M, Sandri C, Gilbert A, Skuck C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399-412
37. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14:395-403
38. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL (2004) IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol 287:E591-E601
39. Solomon V, Goldberg AL (1996) Importance of the ATP-ubiquitin-proteasome pathway in degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 271:26690-26697
40. Du J, Wang X, Meireles CL, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE (2004) Activation of caspase 3 is an initial step triggering muscle proteolysis in catabolic conditions. J Clin Invest 113:115-123
41. Wang XH, Hu Z, Hu JP, Du J, Mitch WE (2006) Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147:4160-4168
42. Workeneh B, Rondon-Berrios H, Zhang L, Hu Z, Ayehu G, Ferrando A, Kopple JD, Wang H, Storer TW, Fournier M, Lee SW, Du J, Mitch WE (2006) Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J Am Soc Nephrol 17:3233-3239
43. Mitch WE, Medina R, Greiber S, May RC, England BK, Price SR, Bailey JL, Goldberg AL (1994) Metabolic acidosis stimulates muscle protein degradation by activating the ATP-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 93:2127-2133
44. DeFronzo RA, Beckles AD (1979) Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 236:E328-E334
45. May RC, Bailey JL, Mitch WE, Masud T, England BK (1996) Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int 49:679-683
46. Hasselgren P-O, Warner BW, James H, Takehara H, Fischer JE (1987) Effect of insulin on amino acid uptake and protein turnover in skeletal muscle from septic rats: Evidence for insulin resistance of protein degradation. Arch Surg 122:228-233
47. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA (2007) Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 71:146-152
48. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3:1014-1019
49. Bailey JL, Price SR, Zheng B, Hu Z, Mitch WE (2006) Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: Implications for muscle atrophy. J Am Soc Nephrol 17:1388-1394
50. Saad MJ, Folli F, Kahn JA, Kahn CR (1993) Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92:2065-2072
51. May RC, Kelly RA, Mitch WE (1986) Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J Clin Invest 77:614-621
52. Wing SS, Goldberg AL (1993) Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 264:E668-E676
53. Price SR, England BK, Bailey JL, Van Vreede K, Mitch WE (1994) Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am J Physiol 267:C955-C960
54. Tiao G, Fagan J, Roegner V, Lieberman M, Wang J-J, Fischer JE, Hasselgren P-O (1996) Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J Clin Invest 97:339-348
55. Mauras N (2001) Growth hormone therapy in the glucocorticosteroid-dependent child: Metabolic and linear growth effects. Horm Res 56(Suppl 1):13-18
56. Neu AM, Bedinger M, Fivush BA, Warady BA, Watkins SL, Friedman AL, Brem AS, Goldstein SL, Frankenfield DL (2005) Growth in adolescent hemodialysis patients: Data from the Centers for Medicare & Medicaid Services ESRD Clinical Performance Measures Project. Pediatr Nephrol 20:1156-1160
57. Mehls O, Schaefer F, Tonshoff B, Wuhl E (2002) Effectiveness of growth hormone treatment in short children with chronic renal failure. J Pediatr 141:147-148
58. Fine RN, Sullivan EK, Tejani A (2000) The impact of recombinant human growth hormone treatment on final adult height. Pediatr Nephrol 14:679-681
59. Fischbach M, Terzic J, Menouer S, Dheu C, Soskin S, Helmstetter A, Burger MC (2006) Intensified and daily hemodialysis in children might improve statural growth. Pediatr Nephrol 21:1746-1752
60. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119:285-298
61. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183-190
62. Lee SJ (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61-86
63. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee S-J (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296:1486-1488
64. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 209:501-514
65. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682-2688
66. Sun DF, Xheng Z, Tummala P, Oh J, Schaefer F, Rabkin R (2004) Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. J Am Soc Nephrol 15:2630-2636
67. Wang H, Casaburi R, Taylor WE, Aboellail H, Storer TW, Kopple JD (2005) Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients. Kidney Int 68:352-361
68. Kalhoff H, Diekmann L, Kunz C, Stock GJ, Manz F (1997) Alkali therapy versus sodium chloride supplement in low birthweight infants with incipient late metabolic acidosis. Acta Paediatr 86:96-101
69. Boirie Y, Broyer M, Gagnadoux MF, Niaudet P, Bresson J-L (2000) Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 58:236-241
70. Reaich D, Channon SM, Scrimgeour CM, Goodship TH (1992) Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol 263:E735-E739
71. Ballmer PE, McNurlan MA, Hulter HN, Anderson SE, Garlick PJ, Krapf R (1995) Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 95:39-45
72. Papadoyannakis NJ, Stefanidis CJ, McGeown M (1984) The effect of the correction of metabolic acidosis on nitrogen and protein balance of patients with chronic renal failure. Am J Clin Nutr 40:623-627
73. Reaich D, Channon SM, Scrimgeour CM, Daley SE, Wilkinson R, Goodship TH (1993) Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 265:E230-E235
74. Garibotto G, Russo R, Sofia A, Sala MR, Robaudo C, Moscatelli P, DeFerrari G, Tizianello A (1994) Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. Kidney Int 45:1432-1439
75. Williams B, Hattersley J, Layward E, Walls J (1991) Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia. Kidney Int 40:779-786
76. Graham KA, Reaich D, Channon SM, Downie S, Goodship TH (1997) Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 8:632-637
77. Movilli E, Zani R, Carli O, Sangalli L, Pola A, Camerini C, Cancarini GC, Scolari F, Feller P, Maiorca R (1998) Correction of metabolic acidosis increases serum albumin concentration and decreases kinetically evaluated protein intake in hemodialysis patients: A prospective study. Nephrol Dial Transplant 13:1719-1722
78. Graham KA, Reaich D, Channon SM, Downie S, Gilmour E, Passlick-Deetjen J, Goodship TH (1996) Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int 49:1396-1400
79. Stein A, Moorhouse J, Iles-Smith H, Baker R, Johnstone J, James G, Troughton J, Bircher G, Walls J (1997) Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 52:1089-1095
80. Challa A, Krieg RJ, Thabet MA, Veldhuis JD, Chan JC (1993) Metabolic acidosis inhibits growth hormone secretion in rats: Mechanism of growth retardation. Am J Physiol 265:E547-E553
81. Brungger M, Hulter HN, Krapf R (1997) Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: New cause of growth hormone insensitivity in humans. Kidney Int 51:216-221
82. Wiederkehr MR, Kalogiros J, Krapf R (2004). Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant 19:1190-1197
83. Kuemmerle N, Krieg RJ, Latta K, Challa A, Hanna JD, Chan JC (1997) Growth hormone and insulin-like growth factor in non-uremic acidosis and uremic acidosis. Kidney Int 58:S102-S105
84. Green J, Maor G (2002) Effect of metabolic acidosis on the growth hormone/IGF-1 endocrine axis in skeletal growth centers. Kidney Int 57:2258-2267
85. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T (2005) Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 45:275-280
86. Mak RH (1998) Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 54:603-607
87. Bereket A, Wilson TA, Kolasa AJ, Fan J, Lang CH (1996) Regulation of the insulin-like growth factor system by acute acidosis. Endocrinology 137:2238-2245
88. Brungger M, Hulter HN, Krapf R (1997) Effect of chronic metabolic acidosis on thyroid hormone homeostasis in humans. Am J Physiol 272:F648-F653
89. Schambelan M, Sebastian A, Katuna A, Arteaga E (2001) Adrenocortical hormone secretory response to chronic NH4Cl-induced metabolic acidosis. Am J Physiol 252:E454-E460
90. Graham KA, Reaich D, Channon SM, Downie S, Goodship TH (1997) Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 8:627-631
91. Krapf R, Vetsch R, Vetsch W, Hulter HN (1992) Chronic metabolic acidosis increases the serum concentration of 1,25-dihydroxyvitamin D in humans by stimulating its production rate. J Clin Invest 90:2456-2463